The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
Open accessAbstract
In vivo protection by antimicrobial neutralizing Abs can require the contribution of effector functions mediated by Fc-Fcγ receptor (Fc-FcγR) interactions for optimal efficacy. In influenza, broadly neutralizing anti-hemagglutinin (anti-HA) stalk mAbs require Fc-FcγR interactions to mediate in vivo protection, but strain-specific anti-HA head mAbs do not. Whether this rule applies only to anti-stalk Abs or is applicable to any broadly neutralizing Ab (bNAb) against influenza is unknown. Here, we characterized the contribution of Fc-FcγR interactions during in vivo protection for a panel of 13 anti-HA mAbs, including bNAbs and non-neutralizing Abs, against both the stalk and head domains. All classes of broadly binding anti-HA mAbs required Fc-FcγR interactions to provide protection in vivo, including those mAbs that bind the HA head and those that do not neutralize virus in vitro. Further, a broadly neutralizing anti-neuraminidase (anti-NA) mAb also required FcγRs to provide protection in vivo, but a strain-specific anti-NA mAb did not. Thus, these findings suggest that the breadth of reactivity of anti-influenza Abs, regardless of their epitope, necessitates interactions with FcγRs on effector cell populations to mediate in vivo protection. These findings will guide the design of antiviral Ab therapeutics and inform vaccine design to elicit Abs with optimal binding properties and effector functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203 · cited 1×
“Thus, recent studies have identified that interactions between the Ab’s constant Fc domain and members of the Fcγ receptor (FcγR) family are required for anti-influenza mAb–mediated protection in vivo (7, 8).”
BackgroundDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Self-citationFcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
Self-citationDiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749
Self-citationAdvances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 597
Self-citationType I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Self-citationCorti, D., Suguitan, A. L., Pinna, D., Silacci, C., Fernandez-Rodriguez, B. M., Vanzetta, F., Santos, C., Luke, C. J., Torres-Velez, F. J., Temperton, N. J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41902 · Cited by 437
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 409
Self-citationEl Bakkouri, K., Descamps, F., De Filette, M., Smet, A., Festjens, E., Birkett, A., Van Rooijen, N., Verbeek, S., Fiers, W., & Saelens, X. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0902147 · Cited by 335
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 307
Self-citationToward a Universal Influenza Virus Vaccine: Prospects and Challenges
Pica, N., & Palese, P. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120611-145115 · Cited by 284
Self-citationThe role of Fc–FcγR interactions in IgG-mediated microbial neutralization
Bournazos, S., DiLillo, D. J., & Ravetch, J. V. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20151267 · Cited by 175
Self-citationWohlbold, T., & Krammer, F. (2014) · Viruses · doi:10.3390/v6062465 · Cited by 166
Wang, T. T., & Palese, P. (2011) · Science · doi:10.1126/science.1210724 · Cited by 25
Self-citation
Cited by
Krammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,570
Self-citationStudies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
The evolution of seasonal influenza viruses
Petrova, V. N., & Russell, C. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.118 · Cited by 846
The human antibody response to influenza A virus infection and vaccination
Krammer, F. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0143-6 · Cited by 796
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
Metadata
- Authors
- DiLillo, D. J., Palese, P., Wilson, P. C., & Ravetch, J. V.
- Venue
- Journal of Clinical Investigation
- Published
- 2016-01-05
- Volume
- 126
- Issue
- 2
- Pages
- 605-610
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2223009545
- Cited by
- 407
- References
- 14
- FWCI
- 45.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.